Every analyst call
Every public market call we’ve tracked, newest first. Filter by instrument, direction, grading status, analyst, firm, or sector — every combination is a shareable link.
Sentiment · Nifty Pharma
Analysts lean bullish
14 analyst stances matching these filters · one per analyst
Trackable
6 · 6 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
8 · 5 bull / 2 neutral / 1 bear
Bullish 78.6% (11)Neutral 14.3% (2)Bearish 7.1% (1)
Date range
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on smaller CDMO (Contract Development and Manufacturing Organisation) companies, expecting them to deliver stron…” | Vishal ManchandaSystematix Group | Nifty Pharma | PENDING | |
| “Bullish on Pharma and CDMO stocks, observing that they continue to find buyers despite elevated valuations. This indicat…” | VK VijayakumarGeojit Investments | Pharma and CDMO | PENDING | |
| “The proposed US tariffs on imported generic medicines create uncertainty for Indian pharmaceutical exporters. While ther…” | Sunny AgrawalSBI Cap Securities | Nifty Pharma | NOT GRADED | |
| “The proposed US tariffs on generic imports, which are not India-specific, are unlikely to significantly impact Indian ph…” | Tushar ManudhaneMotilal Oswal Financial Services | Nifty Pharma | PENDING | |
| “Pharma remains one of the strongest performing sectors, supported by a clear higher-high, higher-low formation and susta…” | Hitesh TailorChoice Equity Broking | Nifty Pharma | NOT GRADED | |
| “Bullish on the Pharma sector, which has broken out of an 18-month consolidation and hit a fresh All-time High. The secto…” | Dharmesh ShahICICI Securities | Nifty Pharma | PENDING | |
| “Pharma is a better dollar play than IT in the current environment, driven by three tailwinds: FII flows, product-specifi…” | Sunil SubramaniamSense and Simplicity | Nifty Pharma | HIT | |
| “Vora allocates 10-12% of his portfolio to the Pharma sector, indicating a bullish stance. While specific rationale isn't…” | Siddharth VoraPL Asset Management | Nifty Pharma | HIT | |
| “The Pharma sector is expected to remain range-bound in the short term, having been in a broad consolidation for the past…” | Rupak DeLKP Securities | Nifty Pharma Index | MISS | |
| “Carnelian maintains large, untrimmed positions in pharma and CDMOs, viewing CDMOs as a robust long-term manufacturing th…” | Vikas KhemaniCarnelian Asset Management & Advisors | Nifty Pharma | PENDING | |
| “Dipan Mehta is positive on Aurobindo Pharma, viewing recent Form 483 observations as not a major concern due to diversif…” | Dipan MehtaElixir Equities | Nifty Pharma | NOT GRADED | |
| “Rohit Srivastava views the pharmaceutical sector as a pure defensive bet during difficult markets. He suggests pharma st…” | Rohit SrivastavaStrike Money Analytics and Indiacharts | Nifty Pharma | MISS | |
| “Solanki identifies a strategic play in the Pharma sector around upcoming generic drug launches in March (India) and Apri…” | Narendra SolankiAnand Rathi Shares & Stock Brokers | Nifty Pharma | MISS | |
| “Dipan Mehta advises investors to be overweight on the broader pharma sector. While acknowledging the good opportunity in…” | Dipan MehtaElixir Equities | Nifty Pharma | MISS | |
| “Nitin Raheja suggests that the pharma sector could see a re-rating in FY27, contingent on supportive valuations. This po…” | Nitin RahejaJulius Baer Wealth Advisors | Nifty Pharma | HIT |